These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17537308)

  • 1. [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
    Zhang PN; Sun H
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):196-200. PubMed ID: 17537308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
    Ren Y; Zha X; Zhang GN
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1204-6. PubMed ID: 17686243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High D-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction].
    Yu P; Yu DM; Qi JC; Wang J; Zhang QM; Zhang JY; Tang YZ; Xing QL; Li MZ
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3425-30. PubMed ID: 17313857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
    Xiao L; He C; Li X; Chen Y; Zhou JD
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):616-20. PubMed ID: 23141184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of human epithelial ovarian cancer HO-8910 cells with modified survivin gene on the cell cycle distribution and chemosensitivity].
    Peng LP; Huang JM; Zhang GN; Zha X; Ren Y; Fan Y; Deng BF
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):860-4. PubMed ID: 21211287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
    Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
    Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of glucose regulated protein 78 on autophagy and apoptosis in ovarian epithelial carcinoma].
    Li M; Tian J; Qu Q
    Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):848-53. PubMed ID: 26887774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
    Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
    Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
    Zhang L; Yang N; Katsaros D; Huang W; Park JW; Fracchioli S; Vezzani C; Rigault de la Longrais IA; Yao W; Rubin SC; Coukos G
    Cancer Res; 2003 Jul; 63(14):4225-31. PubMed ID: 12874030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
    Choi JH; Choi KC; Auersperg N; Leung PC
    Cancer Res; 2006 Apr; 66(7):3912-20. PubMed ID: 16585220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Beta-HIVS combined cisplatin inhibited activities of human ovarian cancer cell line SKOV3 in vitro].
    Zhang J; Shen MH; Ruan SM
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Aug; 34(8):987-90. PubMed ID: 25223186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
    Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
    Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
    Kunnimalaiyaan M; Ndiaye M; Chen H
    Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
    Hu L; Zaloudek C; Mills GB; Gray J; Jaffe RB
    Clin Cancer Res; 2000 Mar; 6(3):880-6. PubMed ID: 10741711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
    Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
    Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.